Appointment Boosts Product to Market Initiative

Biotech technologies provider Nuclera has appointed Dr Joe Keegan to its Board to help develop commercial and financing strategies to grow the company while creating value for investors.

With more than 30 years of experience in life science businesses, Dr Keegan was formerly CEO at life science tool company ForteBio Inc, (2007-2012) before its sale to Pall Corporation and was also CEO at Molecular Devices Inc, (1998-2007), a provider of bioanalytical measurement systems, software and consumables, where he grew the company both internally and through acquisitions. He currently serves on the Board of Arrayjet, Carterra, Fluidic Analytics (Chairman), Halo Labs (Executive Chairman) and serves on the board of Bio-Techne and Interpace Biosciences Inc. He has a BA in Chemistry from Boston University and a PhD in Physical Chemistry from Stanford University.

Dr Jiahao Huang, co-founder of Cambridge-based Nuclera, said: “The ability to attract such exceptional talent to the Nuclera board further validates the vision of the company to provide life science researchers powerful tools to engineer biology. We are delighted that Joe is joining the Nuclera Board. His extensive experience in growing life science technology companies will add real value as Nuclera delivers its plan to bring a benchtop gene and protein printer to the market.”